Cyclerion Therapeutics (CYCN) Return on Capital Employed (2019 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Return on Capital Employed of 37.11% for Q3 2025, up 2567.0% year-over-year from 1.39% in Q3 2024, and up 12.95% quarter-over-quarter from 42.63% in Q2 2025.
Cyclerion Therapeutics (CYCN) Return on Capital Employed (2019 - 2025) Analysis & Trends
Cyclerion Therapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 37.11% for Q3 2025.
- In Q3 2025, Return on Capital Employed rose 2567.0% year-over-year to 37.11%; the TTM figure through Sep 2025 stood at 37.11% (up 2567.0% YoY), while the FY2024 annual figure was 33.75%, up 6119.0% from the prior year.
- Return on Capital Employed for Q3 2025 stood at 37.11%, up from 42.63% in the prior quarter.
- The five-year high for Return on Capital Employed was 35.87% in Q1 2025, with the low at 242.1% in Q2 2023.
- The 5-year median for Return on Capital Employed is 103.34% (2024), against an average of 110.12%.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed sank 11006 bps in 2022, then surged 12747 bps in 2024.
- Cyclerion Therapeutics' Return on Capital Employed stood at 87.59% in 2021, then tumbled by 88 bps to 164.62% in 2022, then soared by 36 bps to 106.08% in 2023, then jumped by 60 bps to 42.62% in 2024, then gained by 13 bps to 37.11% in 2025.
- Business Quant data shows CYCN's Return on Capital Employed at 37.11% in Q3 2025, 42.63% in Q2 2025, and 35.87% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -37.11% |
| Jun 30, 2025 | -42.63% |
| Mar 31, 2025 | -35.87% |
| Dec 31, 2024 | -42.62% |
| Sep 30, 2024 | -62.77% |
| Jun 30, 2024 | -114.62% |
| Mar 31, 2024 | -103.34% |
| Dec 31, 2023 | -106.08% |
| Sep 30, 2023 | -124.90% |
| Jun 30, 2023 | -242.10% |
| Mar 31, 2023 | -175.57% |
| Dec 31, 2022 | -164.62% |
| Sep 30, 2022 | -209.56% |
| Jun 30, 2022 | -167.78% |
| Mar 31, 2022 | -126.12% |
| Dec 31, 2021 | -87.59% |
| Sep 30, 2021 | -99.50% |
| Jun 30, 2021 | -80.54% |
| Mar 31, 2021 | -69.03% |
| Dec 31, 2020 | -76.35% |